Abstract Doxorubicin (DOX), or Adriamycin, an anthracycline antibiotic discovered
serendipitously as a chemotherapeutic drug several decades ago, is still one of the most …

Cancer immunotherapy, which leverages features of the immune system to target neoplastic
cells, has revolutionized the treatment of cancer. The use of these therapies has rapidly …

Tumor cells predominantly express self-antigens and overcoming self-tolerance is the
primary challenge to effective immunotherapy. Tumors also express ligands for co-inhibitory …

Immune checkpoint inhibitors target the inhibitory receptors on T cells to reinstate their
antitumor ability and have shown significant efficacy in treating various cancers. However …

Progress in cancer therapy over the past decades improved long-term survival but increased
cancer therapy-related cardiotoxicity. Many novel treatment options have been implemented …

T lymphocyte-mediated immune responses in the heart are potentially dangerous because
they can interfere with the electromechanical function. Furthermore, the myocardium has …

The evolution of cancer treatment and development of new classes of anticancer therapies
have continued to revolutionize the field of oncology. New therapies including targeted …

Dendritic cells (DCs) can present tumoral antigens to T-cells and stimulate T-cell-mediated
anti-tumoral immune responses. In addition to uptaking, processing, and presenting tumoral …

The emergence of immune checkpoint inhibitors (ICI's) in the past decade has proven
transformative in the area of immuno-oncology. The PD-1/PD-L1 axis has been particularly …

Abstract Background The US Food and Drug Administration (FDA) has approved several
immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in …